Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis

Neurology

Volumn 81, Issue 3, 2013, Pages 206-210

  Kremer, Stéphane ^a,b   Lamy, Julien ^b   Magnus, Antoine ^a   Oesterle, Hélene ^c   Jeantroux, Jeremy ^a   Trunet, Stéphanie ^d   Armspach, Jean Paul ^b   Dietemann, Jean Louis ^a   De Seze, Jérôme ^a,b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Pasteur Hospital   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOFOSVESET; GADOLINIUM; TETRAXETAN GADOLINIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; DRUG SCREENING; FEMALE; HUMAN; MAGNETIC FIELD; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER;

ADULT; CONTRAST MEDIA; FEMALE; GADOLINIUM; HETEROCYCLIC COMPOUNDS; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; ORGANOMETALLIC COMPOUNDS;

EID: 84881296576     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829bfdb9     Document Type: Article

References (17)

1. Eldredge HB, Spiller M, Chasse JM, Greenwood MT, Caravan P. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol 2006;41:229-243
2. Farooki A, Narra V, Brown J. Gadofosveset (EPIX/Schering). Curr Opin Investig Drugs 2004;5:967-976
3. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011;1812:252-264
4. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003;9:540-549
5. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70
6. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
7. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397
8. Kappos L Moeri D Radue EW et al Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis G Lancet 1999 353 964-969.
9. Barkhof F, Polman CH, Radue EW, et al.Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007;64:1292-1298
10. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118
11. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-260
12. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094
13. Adzamli K, Yablonskiy DA, Chicoine MR, et al. Albuminbi nding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Magn Reson Med 2003;49:586-590
14. Essig M, Rohrer M, Giesel F, et al. Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol 2010;20:218-226
15. Bagheri MH, Meshksar A, Nabavizadeh SA, Borhani- Haghighi A, Ashjazadeh N, Nikseresht AR. Diagnostic value of contrast-enhanced fluid-attenuated inversionrecovery and delayed contrast-enhanced brain MRI in multiple sclerosis. Acad Radiol 2008;15:15-23
16. Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M. Sensitivity of immediate and delayed gadoliniumenhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. AJR Am J Roentgenol 2007;188:697-702
17. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120:1149-1161